ALK and lung cancer: Depicting the heterogeneity of ALK lung cancers, there have been more than 50 ALK KDMs described in the literature, with the expected ALKi clinical cross-resistance of these mutations to different ALKi’s becoming better established, with preclinical data informing the expected performance.